ANI Pharmaceuticals Inc (ANIP) revenue by segment
ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3046% below fair value
$71.47+1.48 (+2.11%)
Close on Nov 18, 2026Market cap $1.64BP/E 15.2Yield –
Doanh thu theo bộ phận của ANI Pharmaceuticals Inc
Theo bộ phận kinh doanh
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rare Disease and Brands | $483.93M | $294.34M | $197.50M | $81.15M | – | – | – | – | – | – | 54.8% | +64.4% |
| Generics and Other | $399.43M | $320.03M | $289.31M | $235.24M | – | – | – | – | – | – | 45.2% | +24.8% |
| Generics, Established Brands, and Other | – | – | $374.70M | $274.70M | $216.14M | $208.48M | – | – | – | – | – | – |
| Rare Disease | – | – | $112.12M | $41.69M | $0 | – | – | – | – | – | – | – |
| Canada | – | – | – | – | – | – | $6.88M | $4.69M | $0 | $0 | – | – |
| United States | – | – | – | – | – | – | $199.66M | $196.89M | $176.84M | $128.62M | – | – |
| Lợi nhuận hoạt động | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Generics and Other | $154.99M | $116.02M | $105.93M | $85.48M | – | – | – | – | – | – | +33.6% |
| Rare Disease and Brands | $141.24M | $72.47M | $89.17M | $10.54M | – | – | – | – | – | – | +94.9% |
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rare Disease and Brands total net revenues | $483.95M | $294.34M | $197.50M | $81.15M | – | – | – | – | – | – | 54.8% | +64.4% |
| Rare Disease total net revenues | $422.65M | $229.60M | $112.12M | $41.69M | – | – | – | – | – | – | 47.8% | +84.1% |
| Generics and Other total net revenues | $399.41M | $320.03M | $289.32M | $235.24M | – | – | – | – | – | – | 45.2% | +24.8% |
| Generic pharmaceutical products | $384.11M | $301.00M | $269.45M | $210.12M | $143.57M | $147.26M | $128.73M | $117.45M | $118.44M | $95.20M | 43.5% | +27.6% |
| Cortrophin Gel | $347.78M | $198.09M | $112.12M | $41.69M | – | – | – | – | – | – | 39.4% | +75.6% |
| ILUVIEN and YUTIQ | $74.87M | $31.51M | $0 | $0 | – | – | – | – | – | – | 8.5% | +137.6% |
| Brands | $61.31M | $64.74M | $85.38M | $39.46M | – | – | – | – | – | – | 6.9% | -5.3% |
| Unapproved Products | $24.10M | $22.40M | $22.40M | $14.20M | $16.20M | $16.90M | $20.70M | $24.90M | $27.60M | $34.30M | 2.7% | +7.6% |
| Royalties and other pharmaceutical services | $15.30M | $19.03M | $19.87M | $25.12M | – | – | – | – | – | – | 1.7% | -19.6% |
| Sales of rare disease pharmaceutical products | – | – | $112.12M | $41.69M | $0 | – | – | – | – | – | – | – |
| Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services | – | – | $105.25M | $64.58M | $72.57M | $47.96M | $63.77M | $60.55M | $50.92M | $26.44M | – | – |
| Sales of contract manufactured products | – | – | – | $16.11M | $10.04M | $9.22M | $11.14M | $9.12M | $7.05M | $5.54M | – | – |
| Other | – | – | – | $693.00K | $1.86M | $783.00K | $980.00K | $929.00K | $440.00K | $1.44M | – | – |
| Royalties from licensing agreements | – | – | – | $5.37M | $11.80M | $1.40M | $807.00K | $12.50M | $0 | $0 | – | – |
| Product development services | – | – | – | $2.95M | $1.31M | $1.86M | $1.13M | $1.02M | $0 | $0 | – | – |
| Performance Obligation From Prior Period | – | – | – | – | – | – | $10.20M | $5.30M | – | – | – | – |
Theo khu vực
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $852.44M | $604.99M | $486.25M | $312.43M | $211.89M | $202.88M | $199.66M | $196.89M | – | – | 96.5% | +40.9% |
| International | $30.92M | $9.39M | $565.00K | $3.96M | – | – | – | – | – | – | 3.5% | +229.4% |
| Canada | – | – | $565.00K | $3.96M | $4.24M | $5.59M | $6.88M | $4.69M | – | – | – | – |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của ANI Pharmaceuticals (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của ANI Pharmaceuticals, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?